NRX Pharmaceuticals Inc

NRX Pharmaceuticals’ 3.5% pre‑market rally shows how biotech gains and positive peer sentiment can lift early‑stage stocks, hinting at future upside if clinical milestones and funding materialize.

NRX Pharmaceuticals, a clinical-stage pharmaceutical company, is navigating the challenges of the biotech sector with a focus on developing investigational medicines for critical areas such as Covid-19, respiratory conditions, suicidal depression, a…

NRX Pharmaceuticals continues to advance in clinical research, focusing on treatments for Covid-19, respiratory conditions, suicidal depression, and PTSD.

NRX Pharmaceuticals Inc. has gained significant attention after receiving FDA Fast Track designation for its investigational drug NRX-100, which aims to treat suicidal ideation in patients with depression.